NeoGenomics Q4 EPS $0.04, Halozyme $1.26, IFF $0.97, Herbalife $0.36; Sales $172M, $298M, $2.77B, $1.20B Beat Estimates

NeoGenomics reported its fourth-quarter 2024 earnings with an adjusted EPS of $0.04, surpassing the $0.03 estimate, while sales totaled $172 million, falling short of the $173.18 million estimate. Halozyme Therapeutics also announced its fourth-quarter results, achieving an adjusted EPS of $1.26, exceeding the $1.16 estimate, and sales of $298 million, which beat the $288.24 million estimate. International Flavors & Fragrances (IFF) reported an adjusted EPS of $0.97, beating the estimate of $0.81, with sales reaching $2.77 billion, surpassing the $2.677 billion estimate. However, IFF's net income was reported at a loss of $46 million, with revenue growth across all divisions but a slight decline in operating margin due to reinvestment and cost pressures. Herbalife's fourth-quarter results showed an adjusted EPS of $0.36, beating the $0.22 estimate, and sales of $1.20 billion, which exceeded the $1.19 billion estimate.